EGFR exon 20 insertion mutations display sensitivity to HSP90 inhibition in preclinical models and lung adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. Experimental Design: Preclinical models of a representative set of EGFR exon 20 insertion mutations to evaluate the efficacy of different inhibitors and description of the clinical outcome of an advanced lung cancer. Results: We show that select first-, second-, and third-generation EGFR inhibitors are unable to deter common EGFR exon 20 insertion mutants in concentrations that spare the wild-type kinase. Nonetheless, EGFR exon 20 insertion mutants associate with the Hsp90 chaperone system. We exploit this vulnerability to show that the nongeldanamycin Hsp90 inhibitor luminespib (formerly AUY922) degrades EGFR exon 20 mutations, downstream targets, and induces apoptosis. In addition, a patient whose EGFR inhibitor–insensitive lung adenocarcinoma harbored an EGFR exon 20 insertion mutation had a confirmed radiographic response to luminespib. Conclusions: The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.

Original languageEnglish
Pages (from-to)6548-6555
Number of pages8
JournalClinical Cancer Research
Volume24
Issue number24
DOIs
Publication statusPublished - 2018 Dec 15
Externally publishedYes

Fingerprint

Insertional Mutagenesis
Exons
Mutation
Adenocarcinoma of lung
Lung Neoplasms
Research Design
Phosphotransferases
Clinical Trials
Apoptosis
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

EGFR exon 20 insertion mutations display sensitivity to HSP90 inhibition in preclinical models and lung adenocarcinomas. / Jorge, Susan E.; Lucena-Araujo, Antonio R.; Yasuda, Hiroyuki; Piotrowska, Zofia; Oxnard, Geoffrey R.; Rangachari, Deepa; Huberman, Mark S.; Sequist, Lecia V.; Kobayashi, Susumu S.; Costa, Daniel B.

In: Clinical Cancer Research, Vol. 24, No. 24, 15.12.2018, p. 6548-6555.

Research output: Contribution to journalArticle

Jorge, SE, Lucena-Araujo, AR, Yasuda, H, Piotrowska, Z, Oxnard, GR, Rangachari, D, Huberman, MS, Sequist, LV, Kobayashi, SS & Costa, DB 2018, 'EGFR exon 20 insertion mutations display sensitivity to HSP90 inhibition in preclinical models and lung adenocarcinomas', Clinical Cancer Research, vol. 24, no. 24, pp. 6548-6555. https://doi.org/10.1158/1078-0432.CCR-18-1541
Jorge, Susan E. ; Lucena-Araujo, Antonio R. ; Yasuda, Hiroyuki ; Piotrowska, Zofia ; Oxnard, Geoffrey R. ; Rangachari, Deepa ; Huberman, Mark S. ; Sequist, Lecia V. ; Kobayashi, Susumu S. ; Costa, Daniel B. / EGFR exon 20 insertion mutations display sensitivity to HSP90 inhibition in preclinical models and lung adenocarcinomas. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 24. pp. 6548-6555.
@article{acb63d043b7b41f6bac2f2f140c422e0,
title = "EGFR exon 20 insertion mutations display sensitivity to HSP90 inhibition in preclinical models and lung adenocarcinomas",
abstract = "Purpose: EGFR exon 20 insertions account for up to 10{\%} of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. Experimental Design: Preclinical models of a representative set of EGFR exon 20 insertion mutations to evaluate the efficacy of different inhibitors and description of the clinical outcome of an advanced lung cancer. Results: We show that select first-, second-, and third-generation EGFR inhibitors are unable to deter common EGFR exon 20 insertion mutants in concentrations that spare the wild-type kinase. Nonetheless, EGFR exon 20 insertion mutants associate with the Hsp90 chaperone system. We exploit this vulnerability to show that the nongeldanamycin Hsp90 inhibitor luminespib (formerly AUY922) degrades EGFR exon 20 mutations, downstream targets, and induces apoptosis. In addition, a patient whose EGFR inhibitor–insensitive lung adenocarcinoma harbored an EGFR exon 20 insertion mutation had a confirmed radiographic response to luminespib. Conclusions: The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.",
author = "Jorge, {Susan E.} and Lucena-Araujo, {Antonio R.} and Hiroyuki Yasuda and Zofia Piotrowska and Oxnard, {Geoffrey R.} and Deepa Rangachari and Huberman, {Mark S.} and Sequist, {Lecia V.} and Kobayashi, {Susumu S.} and Costa, {Daniel B.}",
year = "2018",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-18-1541",
language = "English",
volume = "24",
pages = "6548--6555",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - EGFR exon 20 insertion mutations display sensitivity to HSP90 inhibition in preclinical models and lung adenocarcinomas

AU - Jorge, Susan E.

AU - Lucena-Araujo, Antonio R.

AU - Yasuda, Hiroyuki

AU - Piotrowska, Zofia

AU - Oxnard, Geoffrey R.

AU - Rangachari, Deepa

AU - Huberman, Mark S.

AU - Sequist, Lecia V.

AU - Kobayashi, Susumu S.

AU - Costa, Daniel B.

PY - 2018/12/15

Y1 - 2018/12/15

N2 - Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. Experimental Design: Preclinical models of a representative set of EGFR exon 20 insertion mutations to evaluate the efficacy of different inhibitors and description of the clinical outcome of an advanced lung cancer. Results: We show that select first-, second-, and third-generation EGFR inhibitors are unable to deter common EGFR exon 20 insertion mutants in concentrations that spare the wild-type kinase. Nonetheless, EGFR exon 20 insertion mutants associate with the Hsp90 chaperone system. We exploit this vulnerability to show that the nongeldanamycin Hsp90 inhibitor luminespib (formerly AUY922) degrades EGFR exon 20 mutations, downstream targets, and induces apoptosis. In addition, a patient whose EGFR inhibitor–insensitive lung adenocarcinoma harbored an EGFR exon 20 insertion mutation had a confirmed radiographic response to luminespib. Conclusions: The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.

AB - Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. Experimental Design: Preclinical models of a representative set of EGFR exon 20 insertion mutations to evaluate the efficacy of different inhibitors and description of the clinical outcome of an advanced lung cancer. Results: We show that select first-, second-, and third-generation EGFR inhibitors are unable to deter common EGFR exon 20 insertion mutants in concentrations that spare the wild-type kinase. Nonetheless, EGFR exon 20 insertion mutants associate with the Hsp90 chaperone system. We exploit this vulnerability to show that the nongeldanamycin Hsp90 inhibitor luminespib (formerly AUY922) degrades EGFR exon 20 mutations, downstream targets, and induces apoptosis. In addition, a patient whose EGFR inhibitor–insensitive lung adenocarcinoma harbored an EGFR exon 20 insertion mutation had a confirmed radiographic response to luminespib. Conclusions: The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.

UR - http://www.scopus.com/inward/record.url?scp=85057533591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057533591&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1541

DO - 10.1158/1078-0432.CCR-18-1541

M3 - Article

VL - 24

SP - 6548

EP - 6555

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -